TSOLUDOSE 150 micrograms, oral solution in a single-dose container 30 single-dose containers of 1 ml
Active ingredients: Levothyroxine sodium, Levothyroxine sodium
Commercialized according to BDPMDispensing in France: Prescription only
Oral solution30 single-dose containers of 1 mlorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- TSOLUDOSE 150 microgrammes, solution buvable en récipient unidose
- Pharmaceutical form
- solution buvable
- Route of administration
- orale
- Presentation description
- 30 récipients unidoses en polyéthylène basse densité (PEBD) de 1 mL conditionnés en sachets de 5 récipients unidoses
- Marketing authorisation holder
- IBSA PHARMA SAS
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 28 Feb 2025
- Prescription and dispensing conditions
- Prescription only
- List II: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
60254754CIP73016516CIP133400930165164Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| LÉVOTHYROXINE SODIQUEsolution | — | SA |
| LÉVOTHYROXINE SODIQUE ANHYDREsolution | 150 microgrammes · 1 mL de solution | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.